CM  Vol.6 No.1 , March 2015
C5L2 Deficiency Enhances Development of Atherosclerosis in ApoE Knockout Mice
Abstract: Background: The complement system is important in development of atherosclerosis via regulation of lipid and glucose metabolism as well as inflammation. Aim: The aim of the present study was to further analyze the contribution of C5L2 to the development of atherosclerosis. We proposed that, with DIO feeding, C5L2 deficiency would promote a phenotype that encourages atherosclerosis development. Coupled to ApoE deficiency, double knockout (2KO) mice would show exacerbated atherosclerotic plaque formation. Methods: First, Wildtype (WT) and C5L2-/-(C5L2KO) and subsequently, ApoE-/-(ApoEKO) and C5L2/ApoE double knockout mice were placed on diets inducing obesity (DIO) or standard chow diet for 12 - 15 weeks. Plasma lipids, glucose, cytokines and hepatic glycogen and lipid contents, mRNA levels and enzyme activities and atherosclerotic plaque size were measured. Results: C5L2KO had increased hepatic glucose oxidation (+90%, p < 0.001), reduced liver glycogen content on chow diet (-34%, p < 0.05) but increased with DIO (+51%, p < 0.05) vs WT. Glucose clearance was delayed in C5L2/ApoE-2KO vs ApoEKO mice with chow (p < 0.0001) and DIO diet (p = 0.0026). C5L2KO mice had increased hepatic lipid content and fatty acid synthesis but decreased lipid oxidation vs WT. Plasma cholesterol was further elevated in C5L2/ApoE-2KO vs ApoEKO with DIO feeding (p < 0.05). Hepatic cytokine expression was increased in C5L2KO mice compared to WT mice. Atherosclerotic plaque size was increased in C5L2/ ApoE-2KO mice compared with apoEKO on chow (p < 0.05) and DIO regimen (p < 0.001). Conclusions: C5L2 disruption worsens glucose and lipid metabolism, increases hepatic and circulating inflammation, and aggravates atherosclerosis.
Cite this paper: Liu, Y. , Fisette, A. , Lapointe, M. and Cianflone, K. (2015) C5L2 Deficiency Enhances Development of Atherosclerosis in ApoE Knockout Mice. Chinese Medicine, 6, 61-74. doi: 10.4236/cm.2015.61007.

[1]   Glass, C. and Witztum, J. (2001) Atherosclerosis. The Road Ahead. Cell, 104, 503-516.

[2]   Packard, R.R., Lichtman, A.H. and Libby, P. (2009) Innate and Adaptive Immunity in Atherosclerosis. Seminars in Immunopathology, 31, 5-22.

[3]   Libby, P., Ridker, P.M. and Hansson, G.K. (2011) Progress and Challenges in Translating the Biology of Atherosclerosis. Nature, 473, 317-325.

[4]   Hess, K. (2015) The Vulnerable Blood. Coagulation and Clot Structure in Diabetes Mellitus. Hamostaseologie, 35, 25-33.

[5]   Hertle, E., Stehouwer, C.D. and van Greevenbroek, M.M. (2014) The Complement System in Human Cardiometabolic Disease. Molecular Immunology, 61, 135-148.

[6]   Onat, A., Can, G., Rezvani, R. and Cianflone, K. (2011) Complement C3 and Cleavage Products in Cardiometabolic Risk. Clinica Chimica Acta, 412, 1171-1179.

[7]   Gauvreau, D., Gupta, A., Fisette, A., Tom, F.Q. and Cianflone, K. (2013) Deficiency of C5L2 Increases Macrophage Infiltration and Alters Adipose Tissue Function in Mice. PLoS One, 8, e60795.

[8]   Kalant, D., et al. (2014) C5L2 Is a Functional Receptor for Acylation-Stimulating Protein. The Journal of Biological Chemistry, 280, 23936-23944.

[9]   Kalant, D., et al. (2003) Thechemoattractant Receptor-Like Protein C5L2 Binds the C3a des-Arg77/acylation-Stimulating Protein. The Journal of Biological Chemistry, 278, 11123-11129.

[10]   Murray, I., Sniderman, A.D., Havel, P.J. and Cianflone, K. (1999) Acylation Stimulating Protein (ASP) Detciency Alters Postprandial and Adipose Tissue Metabolism in Male Mice. The Journal of Biological Chemistry, 274, 36219-36225.

[11]   Paglialunga, S., Schrauwen, P., Roy, C., Moonen-Kornips, E., Lu, H., Hesselink, M.K.C., Deshaies, Y., Richard, D. and Cianflone, K. (2007) Reduced Adipose Tissue Triglyceride Synthesis and Increased Muscle Fatty Acid Oxidation in C5L2 Knockout Mice. Journal of Endocrinology, 194, 293-304.

[12]   Roy, C., Paglialunga, S., Schaart, G., Moonen-Kornips, E., Meex, R.C., Phielix, E., et al. (2013) Relationship of C5L2 Receptor to Skeletal Muscle Substrate Utilization. PLoS ONE, 8, e57494.

[13]   Fisette, A., Munkonda, M.N., Oikonomopoulou, K., Paglialunga, S., Lambris, J.D. and Cianflone, K. (2013) C5L2 Receptor Disruption Enhances the Development of Diet-Induced Insulin Resistance in Mice. Immunobiology, 218, 127-133.

[14]   Monk, P.N., Scola, A.M., Madala, P. and Fairlie, D.P. (2007) Function, Structure and Therapeutic Potential of Complement C5a Receptors. British Journal of Pharmacology, 152, 429-448.

[15]   Hsu, W.C., Yang, F.C., Lin, C.H., Hsieh, S.L. and Chen, N.J. (2014) C5L2 Is Required for C5a-Triggered Receptor Internalization and ERK Signaling. Cellular Signalling, 26, 1409-1419.

[16]   Wang, R., Lu, B., Gerard, C. and Gerard, N.P. (2013) Disruption of the Complement Anaphylatoxin Receptor C5L2 Exacerbates Inflammation in Allergic Contact Dermatitis. Journal of Immunology, 191, 4001-4009.

[17]   Speid, W.S., Kastl, S.P., Hutter, R., Katsaros, K.M., Kaun, C., Bauriedel, G., Maurer, G., Huber, K., Badimon, J.J. and Wojta, J. (2011) The Complement Component C5a Is Present in Human Coronary Lesions in Vivo and Induces the Expression of MMP-1 and MMP-9 in Human Macrophages in Vitro. FASEB Journal, 25, 35-44.

[18]   Speidl, W.S., Exner, M., Amighi, J., Kastl, S.P., Zorn, G., Maurer, G., et al. (2005) Complement Component C5a Predicts Future Cardiovascular Events in Patients with Advanced Atherosclerosis. European Heart Journal, 26, 2294-2299.

[19]   Wezel, A., de Vries, M.R., Maxime Lagraauw, H., Foks, A.C., Kuiper, J., Quax, P.H.A. and Bot, I. (2014) Complement Factor C5a Induces Atherosclerotic Plaque Disruptions. Journal of Cellular and Molecular Medicine, 18, 2020-2030.

[20]   Clarke, M.C., Figg, N., Maguire, J.J., Davenport, A.P., Goddard, M., Littlewood, T.D. and Bennett, M.R. (2006) Apoptosis of Vascular Smooth Muscle Cells Induces Features of Plaque Vulnerability in Atherosclerosis. Nature Medicine, 12, 1075-1080.

[21]   Bieghs, V., Rensen, P.C., Hofker, M.H. and Shiri-Sverdlov, R. (2012) NASH and Atherosclerosis Are Two Aspects of a Shared Disease: Central Role for Macrophages. Atherosclerosis, 220, 287-293.

[22]   Joven, J., Rull, A., Ferré, N., Escolà-Gil, J.C., Marsillach, J., Coll, B., et al. (2007) The Results in Rodent Models of Atherosclerosis Are Not Interchangeable: The Influence of Diet and Strain. Atherosclerosis, 195, e85-e92.

[23]   Tous, M., Ferre, N., Camps, J., Riu, F. and Joven, J. (2005) Feeding Apolipoprotein E-Knockout Mice with Cholesterol and Fat Enriched Diets May Be a Model of Non-Alcoholic Steatohepatitis. Molecular and Cellular Biochemistry, 268, 53-58.

[24]   Manthey, H.D., Thomas, A.C., Shiels, I.A., Zernecke, A., Woodruff, T.M., Rolfe, B. and Taylor, S.M. (2011) Complement C5a Inhibition Reduces Atherosclerosis in ApoE-/-Mice. FASEB Journal, 25, 2447-2455.

[25]   Roy, C., Paglialunga, S., Fisette, A., Schrauwen, P., Moonen-Kornips, E., St-Onge, J., et al. (2008) Shift in Metabolic Fuel in Acylation-Stimulating Protein-Deficient Mice Following a High-Fat Diet. American Journal of Physiology— Endocrinology and Metabolism, 294, E1051-E1059.

[26]   Murray, I., Parker, R.A., Kirchgessner, T.G., Tran, J., Zhang, Z.J., Westerlund, J. and Cianflone, K. (1997) Functional Bioactive Recombinant Acylation Stimulating Protein Is Distinct from C3a Anaphylatoxin. Journal of Lipid Research, 38, 2492-2501.

[27]   Marcus, F. and Hosey, M.M. (1980) Purification and Properties of Liver Fructose 1,6-Bisphosphatase from C57Bl-KsJ Normal and Diabetic Mice. Journal of Biological Chemistry, 255, 2481-2486.

[28]   Festuccia, W.T., Blanchard, P.G., Turcotte, V., Laplante, M., Sariahmetoglu, M., Brindley, D.N., et al. (2009) The PPARγ Agonist Rosiglitazone Enhances Rat Brown Adipose Tissue Lipogenesis from Glucose without Altering Glucose Uptake. American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, 296, R1327-R1335.

[29]   Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., et al. (2009) The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clinical Chemistry, 55, 611-622.

[30]   Choi, C.S., Savage, D.B., Kulkarni, A., Yu, X.X., Liu, Z.X., Morino, K., et al. (2007) Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-Induced Hepatic Steatosis and Insulin Resistance. Journal of Biological Chemistry, 282, 22678-22688.

[31]   Monetti, M., Levin, M.C., Watt, M.J., Sajan, M.P., Marmor, S., Hubbard, B.K., et al. (2014) Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver. Cell Metabolism, 6, 69-78.

[32]   DeFronzo, R.A. (2010) Insulin Resistance, Lipotoxicity, Type 2 Diabetes and Atherosclerosis: The Missing Links. The Claude Bernard Lecture 2009. Diabetologia, 53, 1270-1287.

[33]   Targher, G. and Arcaro, G. (2007) Non-Alcoholic Fatty Liver Disease and Increased Risk of Cardiovascular Disease. Atherosclerosis, 191, 235-240.

[34]   Tous, M., Ferré, N., Rull, A., Marsillach, J., Coll, B., Alonso-Villaverde, C., Camps, J. and Joven, J. (2006) Dietary Cholesterol and Differential Monocyte Chemoattractant Protein-1 Gene Expression in Aorta and Liver of Apo E-Deficient Mice. Biochemical and Biophysical Research Communications, 340, 1078-1084.

[35]   Samstad, E.O., Niyonzima, N., Nymo, S., Aune, M.H., Ryan, L., Bakke, S.S., et al. (2014) Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release. Journal of Immunology, 192, 2837-2845.

[36]   Kleemann, R., Verschuren, L., van Erk, M.J., Nikolsky, Y., Cnubben, N.H.P., Verheij, E.R., et al. (2007) Atherosclerosis and Liver Inflammation Induced by Increased Dietary Cholesterol Intake: A Combined Transcriptomics and Metabolomics Analysis. Genome Biology, 8, R200.

[37]   Persson, L., Borén, J., Robertson, A.K.L., Wallenius, V., Hansson, G.K. and Pekna, M. (2004) Lack of Complement Factor C3, but Not Factor B, Increases Hyperlipidemia and Atherosclerosis in Apolipoprotein E-/-Low-Density Lipoprotein Receptor-/-Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1062-1067.

[38]   Poursharifi, P., Lapointe, M., Pétrin, D., Devost, D., Gauvreau, D., Hébert, T.E. and Cianflone, K. (2013) C5L2 and C5aR Interaction in Adipocytes and Macrophages: Insights into Adipoimmunology. Cellular Signalling, 25, 910-918.

[39]   Oksjoki, R., Laine, P., Helske, S., Vehmaan-Kreula, P., Mäyränpää, M.I., Gasque, P., et al. (2007) Receptors for the Anaphylatoxins C3a and C5a in Human Atherosclerotic Coronary Plaques. Atherosclerosis, 195, 90-99.

[40]   Shagdarsuren, E., Bidzhekov, K., Mause, S.F., Simsekyilmaz, S., Polakowski, T., Hawlisch, H., et al. (2010) C5a Receptor Targeting in Neointima Formation after Arterial Injury in Atherosclerosis-Prone Mice. Circulation, 122, 1026-1036.